The proportions of HER2–0 and HER2-low were not the same between HR+ and HR- breast cancers, and in the HR+ tumors HER2-low in 107 cases (69.03%) and 74 cases (57.81%) in HR- tumors. The gene discussed is ERBB2; the disease is breast carcinoma.